Organogenesis Holdings Inc. Q2 2026 Earnings Recap

Shares of Organogenesis Holdings plunged 21.5% following the Q2 2026 earnings release, driven primarily by a significant revenue decline and slower-than-expected recovery in the skin substitute market amid ongoing reimbursement headwinds from recent CMS policy changes.

Key Takeaways

• Total revenue fell 58% year-over-year, largely due to a 61% plunge in Advanced Wound Care product sales.
• Although there was an 18% sequential increase in net product revenue quarter-over-quarter, this improvement was insufficient to offset continued year-over-year pressure.
• The 30% increase in wound care unit volumes quarter-over-quarter reflects market share gains but within an overall contracting market.
• CMS policy reforms since late 2025 continue to suppress market demand and delay recovery; management acknowledged revenue fell short of previous expectations.
• The company is pursuing strategic cost reductions and investing in clinical evidence development while exploring new markets with its ReNu program, though these initiatives have yet to offset near-term headwinds.